5.02
전일 마감가:
$4.83
열려 있는:
$4.83
하루 거래량:
198.53K
Relative Volume:
3.03
시가총액:
$96.25M
수익:
-
순이익/손실:
$-33.63M
주가수익비율:
-2.625
EPS:
-1.9124
순현금흐름:
$-47.63M
1주 성능:
+12.56%
1개월 성능:
+6.58%
6개월 성능:
+39.44%
1년 성능:
+79.93%
폴리피드 Stock (PYPD) Company Profile
Compare PYPD vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
PYPD
Polypid Ltd
|
5.02 | 92.61M | 0 | -33.63M | -47.63M | -1.9124 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
폴리피드 Stock (PYPD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-05 | 개시 | Roth Capital | Buy |
| 2025-06-02 | 재개 | H.C. Wainwright | Buy |
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2021-09-14 | 개시 | JMP Securities | Mkt Outperform |
| 2021-07-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-24 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | 개시 | Alliance Global Partners | Buy |
| 2020-07-21 | 개시 | BMO Capital Markets | Outperform |
| 2020-07-21 | 개시 | Barclays | Overweight |
| 2020-07-21 | 개시 | Raymond James | Outperform |
모두보기
폴리피드 주식(PYPD)의 최신 뉴스
PolyPid Q1 earnings call highlights - MSN
PolyPid (PYPD) Jumps 3.93% as Stock Approaches Key Resistance LevelSupport Level Bounce - Newser
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference - Yahoo Finance
PolyPid’s Earnings Call Signals Tightrope to Approval - TipRanks
PolyPid Ltd stock (US70450B1035): pivotal Phase 3 data and Nasdaq listing shift in focus - AD HOC NEWS
PolyPid Submits D-PLEX100 New Drug Application to FDA - HarianBasis.co
PolyPid Ltd.Ordinary Shares (NQ: PYPD - FinancialContent
PolyPid stock (US70450B1035): NDA submission advances D-PLEX100 toward FDA review - AD HOC NEWS
PolyPid Ltd. (NASDAQ:PYPD) Q1 2026 Earnings Call Transcript - Insider Monkey
PYPD Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
PolyPid Earnings Call: NDA Momentum Amid Cash Strain - TipRanks
PolyPid Q1 Earnings Call Highlights - sharewise.com
PolyPid Ltd. Q1 2026 Earnings Call Summary - Yahoo Finance
PolyPid Q1 2026 Earnings Call Transcript - MarketBeat
PYPD: NDA submission for D-PLEX100 nears completion as financials improve and commercialization advances - TradingView
PolyPid Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
PolyPid Q1 2026 Earnings Call: Complete Transcript - Benzinga
[6-K] PolyPid Ltd. Current Report (Foreign Issuer) | PYPD SEC FilingForm 6-K - Stock Titan
PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results - marketscreener.com
PolyPid Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
PolyPid Ltd (PYPD) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Rosalind Advisors/Fund report 9.9% in PolyPid (PYPD) via warrants and shares - Stock Titan
TradingKey - TradingKey
PolyPid Ltd expected to post a loss of 43 cents a shareEarnings Preview - TradingView
Number of shareholders of PolyPid Ltd. – NASDAQ:PYPD - TradingView
How sustainable is PolyPid (PYPD) profit margins? (Smart Money Exits) 2026-05-08Street Ratings - newser.com
PolyPid (PYPD.US) will release its earnings report before the market opens on May 13. - Moomoo
PolyPid to Announce First Quarter 2026 Financial Results on May 13 and Host Conference Call at 8:30 AM ET - geneonline.com
PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026 - The Manila Times
Aurum holds 5,001,561 shares in Polypid Ltd. (PYPD) with exercisable warrants - Stock Titan
AIGH Capital Management LLC Has $5.83 Million Stock Position in PolyPid Ltd. $PYPD - MarketBeat
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting - BioSpace
PolyPid to present wound infection data at surgery conference By Investing.com - Investing.com South Africa
PolyPid to present wound infection data at surgery conference - Investing.com
PolyPid to Present Data from SHIELD II Phase 3 Trial - GlobeNewswire
PYPD Price Today: PolyPid Ltd. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Short Interest in PolyPid Ltd. (NASDAQ:PYPD) Increases By 166.1% - MarketBeat
PYPD (PolyPid Ltd. Ordinary Shares) reports wider than expected Q4 2025 loss, yet shares rise modestly in today’s trading.Pro Trader Recommendations - Cổng thông tin điện tử tỉnh Tây Ninh
PolyPid (PYPD) Stock Outlook | Q4 2025: Earnings UnderperformHigh Growth - Cổng thông tin điện tử tỉnh Lào Cai
PolyPid Ltd stock (US70450B1035): Is its drug-delivery tech strong enough to unlock biotech upside? - AD HOC NEWS
PolyPid Ltd stock (US70450B1035): Is its drug delivery tech strong enough to unlock surgical market - AD HOC NEWS
Nir Dror Darwish Net Worth (2026) - GuruFocus
Itzhak Krinsky Net Worth (2026) - GuruFocus
PolyPid (PYPD) Stock Recovery Underway (-1.27%) 2026-04-16Hot Momentum Watchlist - Cổng thông tin điện tử tỉnh Lào Cai
Yechezkel Barenholz Net Worth (2026) - GuruFocus
Dikla Czaczkes Akselbrad Net Worth (2026) - GuruFocus
Jonathan Missulawin Net Worth (2026) - GuruFocus
Yitzchak Shlomo Jacobovitz Net Worth (2026) - GuruFocus
PolyPid To Present Phase 3 SHIELD II Data Showing Sustained Local Doxycycline Release And Minimal Systemic Exposure At ESCMID 2026 Conference - Sahm
Roth MKM Maintains PolyPid(PYPD.US) With Buy Rating, Maintains Target Price $9 - Moomoo
PolyPid to present D-PLEX100 pharmacokinetic data at ESCMID Global By Investing.com - Investing.com Australia
폴리피드 (PYPD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):